Quick Facts

Тримедат, which contains the active ingredient trimebutine, is a medication indicated for the symptomatic management of specific gastrointestinal disorders. Its primary use is to help relieve the abdominal pain, discomfort, and irregular bowel movements associated with Irritable Bowel Syndrome (IBS), also known as spastic colon.

The medication serves as an option to support the restoration of normal intestinal transit in the period following certain types of abdominal surgery, a condition referred to as paralytic ileus. Additionally, it may be utilized to help manage symptoms of functional dyspepsia, which involves recurrent signs of indigestion that are not attributable to a structural disease.

Trimebutine may modulate motility within the digestive tract, offering a pathway to help coordinate muscle contractions to support bowel function, whether hyper- or hypo-active. All usage and administration must be directed and monitored by a qualified healthcare professional.

Eligibility Profile: Who Can and Cannot Use Trimebutine Maleate

This section summarizes the official population eligibility and non-eligibility information for Trimebutine maleate, based strictly on government regulatory documents where the medicine is authorized.

Absolute Contraindications

Trimebutine maleate must not be used in the following populations:

• Individuals with known hypersensitivity or allergy to the active substance (Trimebutine maleate) or any other ingredient (excipients) in the formulation.
• Children under 2 years of age.

Restricted or Conditional Use

Use is restricted or requires special consideration in these groups:

• Pregnancy: Use is contraindicated during the first trimester. For the second and third trimesters, use is generally not recommended and should only occur if deemed absolutely necessary by a healthcare professional.
• Breastfeeding/Lactation: Use is not recommended, as the passage of the substance into breast milk is not fully known.
• Hereditary Metabolic Disorders: Due to excipients like lactose found in some formulations, the medicine is contraindicated for patients with specific rare hereditary problems, including total lactase deficiency or glucose-galactose malabsorption.

Trimebutine, the active component of Trimebutine, can interact with several other medications, which may affect its efficacy or alter the effects of the co-administered drug. Informing your healthcare provider about all medications, supplements, and herbal products you are taking is essential to manage potential interactions safely.

Potential Drug Interactions

Simultaneous use of Trimebutine with certain nonsteroidal anti-inflammatory drugs (NSAIDs) may also increase the risk of hyperkalemia. Due to the potential for enhanced sedation, caution should be exercised with substances that cause drowsiness, including alcohol and certain anxiolytics. Always consult your doctor before starting or stopping any medication while on Trimebutine therapy.

Тримедат (trimebutine) is a multimodal agent that primarily targets the smooth musculature and enteric nervous system of the gastrointestinal tract. The compound, along with its active metabolite, functions as an agonist at peripheral mu-, kappa-, and delta-opioid receptors located within the enteric plexus. This binding modulates the release of various gastrointestinal peptides and neurotransmitters, contributing to a non-selective regulation of motility.

Simultaneously, trimebutine acts as a modulator of ion channel activity in gastrointestinal smooth muscle cells. It inhibits the influx of calcium ions via voltage-gated L-type calcium channels, which diminishes excitation-contraction coupling, thereby reducing the amplitude of spontaneous contractions. The drug also inhibits calcium-dependent and delayed rectifier potassium channels, which modulates the resting membrane potential and cellular excitability. This dual action on both opioid receptors and ion channels results in the systemic modulation of gastrointestinal transit, capable of either accelerating or decelerating segment-specific contractile patterns, including the induction of a premature phase III of the migrating motor complex.

Administration and Official Dosing Guidelines

The administration of Trimebutine Maleate (Тримедат) involves a defined method, dosage, and timing. The medication is intended for the oral route of administration, typically available as film-coated tablets at strengths such as 100 mg and 200 mg of the active ingredient.

Standard Adult Regimen and Frequency

The standard dosing regimen for adult patients generally involves a typical dose of 100 mg to 200 mg per administration. The frequency is commonly set at three times daily to ensure consistent coverage, with the total intake administered in divided doses. The maximum dose for adults is generally set at 600 mg per day.

Timing and Special Handling

The administration of the immediate-release tablet form is usually specified to occur before meals. For patients using prolonged-release tablets, the physical structure of the dosage form must be preserved, meaning they must be swallowed whole and not crushed or chewed, to maintain the intended time-release function. Dosing for pediatric patients is often determined by body weight, and the standard adult dose applies specifically to that population.

In the event of a missed dose, the standard approach is to take the dose as soon as it is remembered, unless it is close to the next scheduled time. To avoid exceeding the maximums, a missed dose should be skipped entirely in that instance, and doses must never be doubled to compensate.

Research evidence / Overview of studies for Тримедат

Evidence for use in Irritable Bowel Syndrome (IBS)

The clinical evaluation of Trimebutine has included short-term Randomized Controlled Trials (RCTs) and systematic reviews exploring how symptoms change over time in adult populations with IBS. Research examined patient-reported outcomes describing perceived discomfort, such as abdominal pain and bloating. Findings describe patterns observed in the studies over short follow-up periods, typically ranging from four to eight weeks. Some systematic reviews indicate that findings were mixed regarding measurements of overall symptom change. The evidence is limited regarding the use across all IBS sub-types, and long-term effects are not fully established.

Evidence for use in Functional Dyspepsia

Trimebutine was studied for symptoms of Functional Dyspepsia (FD), a condition marked by functional limitations. Research explored Trimebutine in placebo-controlled RCTs and studies examining patient-reported experiences of epigastric pain and fullness. Research also monitored functional outcomes related to the gastric emptying rate. Outcomes were evaluated in both adults and, in some cases, in pediatric patients (children and adolescents). Data for certain groups remain insufficient, and follow-up durations were often limited.

Evidence for use in Post-operative Ileus

Research examined Trimebutine in trials focusing on patients recovering from abdominal surgery. Studies monitored functional measures, specifically the time to first flatus or defecation, in research exploring short-term symptom changes. The evidence focuses on the acute, short-term recovery period immediately following surgery. The results apply only to the populations studied and to the acute IV administration setting.

Research Gaps and Unanswered Questions

Evidence quality varies across studies, with some older trials showing methodological heterogeneity. This variability means findings were mixed in some systematic reviews, making certainty remain low in certain areas. Furthermore, research examined short-term symptom change outcomes more frequently than long-term or maintenance outcomes. The overall evidence base highlights what is known—and what is still uncertain—about the long-term patterns and overall consistency of findings related to physical discomfort.

Key Studies & References

1. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines (Summary of Evidence Review)

Common questions about Тримедат (FAQ)

Q: What is the active ingredient in Тримедат?

The official product information states that the active ingredient in Тримедат is trimebutine maleate. This component is officially described as a regulator of gut motility, meaning it helps normalize the movement of the digestive tract.

Q: What is Тримедат used for?

Regulatory documents indicate that Тримедат is prescribed for functional disorders of the gastrointestinal tract (GIT). This includes conditions such as irritable bowel syndrome (IBS), as well as discomfort and pain linked to GIT motility issues.

Q: Can I use Тримедат if I am pregnant?

According to the official product information, the use of Тримедат is generally not recommended during the first three months of pregnancy. For the second and third trimesters, the official recommendation is for the prescribing physician to carefully assess the potential benefit against the risks. Regulatory documents emphasize that use during pregnancy should only occur under medical oversight.

Q: Can children use Тримедат?

Official information for Тримедат indicates that the product can be used in pediatric patients. However, the approved dosage form and specific age limitations can vary by country and are detailed in the product instructions. The precise age criteria should be confirmed in the specific product instructions.

Q: How does Тримедат work on the digestive system?

Studies and official information indicate that trimebutine maleate acts on the smooth muscle of the digestive tract. It is classified as a regulator of gut motility, which is intended to help normalize both overly active and sluggish movements, to help address symptoms like pain and discomfort.

The storage and disposal of Trimebutine (Тримедат) must follow the specific instructions provided in the official regulatory documentation to maintain its stability and ensure safety.

Official Storage Conditions

Disposal and Child Safety

It is mandatory to keep this medicine out of the sight and reach of children to prevent accidental ingestion. When discarding unused or expired tablets, regulatory guidelines state the product must not be thrown away via household waste or wastewater. Instead, the medicine should be taken to a pharmacist or designated collection point for disposal in accordance with local and national regulations.